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  19 
Abstract 20 
Traffic-related air pollution is a complex mixture of particulate matter (PM) and gaseous 21 
pollutants, such as nitrogen dioxide (NO2). PM exposure contributes to the pathogenesis of 22 
many diseases including several types of cancer, as well as pulmonary, cardiovascular and 23 
neurodegenerative diseases. Also exposure to NO2 has been related to increased cardiovascular 24 
mortality. In search of an early diagnostic biomarker for improved air pollution-associated health 25 
risk assessment, recent human studies have shown that certain circulating miRNAs are altered 26 
upon exposure to traffic-related air pollutants. Here, we present for the first time a global 27 
analysis of the circulating miRNA genome in an experimental cross-over study of a human 28 
population exposed to traffic-related air pollution. By utilizing next-generation sequencing 29 
technology and detailed real-time exposure measurements we identified 54 circulating miRNAs 30 
to be dose- and pollutant species-dependently associated with PM10, PM2.5, black carbon, 31 
ultrafine particles and NO2 already after 2 hours of exposure. Bioinformatics analysis suggests 32 
that these circulating miRNAs actually reflect the adverse consequences of traffic pollution-33 
induced toxicity in target tissues including the lung, heart, kidney and brain. This study shows 34 
the strong potential of circulating miRNAs as novel biomarkers for environmental health risk 35 
assessment. 36 
Keywords: air pollution; diesel exhaust; extracellular microRNAs; biomarkers; health risk 37 
assessment; liquid biopsies 38 
  39 
Introduction 40 
Numerous epidemiological studies have associated exposure to traffic-related air pollution 41 
(TRAP) with increased risk of cardiovascular disease1,2, respiratory disease3,  several types of 42 
cancer, including lung and breast cancer4,5, and more recently also of neurodegenerative 43 
diseases6,7 and kidney disease8. A number of gaseous pollutants such as nitrogen dioxide (NO2) 44 
as well as particulate matter components (PM) are routinely monitored to characterize TRAP 45 
exposure. PM is a complex mixture of fine particles with a diameter of 10 μm or less (PM10), a 46 
diameter of 2.5 μm or less (PM2.5), black carbon (BC), ultrafine particles with a diameter of 0.1 47 
μm or less (UFP) and soot9. Upon inhalation PM penetrates deeply into the lungs from where, 48 
depending on their size, particles are capable of entering the circulation and being distributed to 49 
distal organs such as the heart, spleen or liver9-11. It has even been reported that ultrafine PM 50 
crosses the blood-brain barrier and translocates from the circulation to the brain12. Further, it has 51 
been demonstrated that PM triggers oxidative stress in the respiratory tract and that this might 52 
induce a systemic inflammatory cascade, thus increasing the risk for respiratory and 53 
cardiovascular diseases13. Presumably, pollutants, once distributed over the whole body, may 54 
cause a similar cascade of oxidative stress and inflammation in target organs, thereby increasing 55 
risks for cancer and neurodegenerative disease14. However, the precise molecular mechanisms 56 
that link TRAP exposure to increased disease risks are still poorly understood which hampers the 57 
development of dedicated biomarkers capable of informing on relevant molecular mechanisms of 58 
action.  59 
Several studies have thus highlighted the impact of environmental exposure on gene expression 60 
profiles15, DNA-methylation patterns16, and p53 status17. More recently, environmental 61 
exposure-induced alterations in microRNA (miRNA) levels have been described18. These small 62 
non-coding RNAs are involved in the posttranscriptional regulation of gene expression, and 63 
consequently are involved in virtually all cellular processes19. Furthermore, while these fine-64 
tuners of gene expression are capable of adjusting to internal and external conditions, they also 65 
exhibit tissue/organ specific expression patterns20.  As a consequence of organ injury, cells may 66 
leak their content including the highly stable protein-bound miRNAs, into the peripheral 67 
circulation21. Given the fact that certain miRNAs  are more abundantly expressed in specific 68 
organs, circulating miRNA (cmiRNA) signatures may thus also reflect organ-specific responses 69 
to exposure22. Furthermore, through active secretion, extracellular vesicle-bound cmiRNAs may 70 
act as mediators in intercellular and interorgan communication23. Therefore, cmiRNAs leaked or 71 
released from organs into the circulation, have become a new promising class of biomarkers 72 
capable of non-invasively  interrogating organ pathogenesis and organ-toxic mechanisms from 73 
so called ‘liquid biopsies’22.  74 
To date, most reported air pollution-induced changes in miRNA expression have been identified 75 
in solid tissues in animal models24. The first evidence on PM exposure-related modifications in 76 
cmiRNA levels in humans was provided through investigating healthy steel plant workers. This 77 
study identified 2 vesicle-associated miRNAs that were elevated after occupational exposure to 78 
metal-rich PM13. Additionally, a study on long term exposure to ambient air pollution (6 month 79 
or 1 year) identified the elevation of 5 vesicle-associated cmiRNAs in the serum of healthy 80 
subjects25. Another study among children identified 2 cmiRNAs in the extracellular fraction of 81 
saliva to be significantly altered with long-term ultrafine PM exposure26. 82 
These studies provided evidence that the extracellular miRNA genome (miRNome) is affected 83 
by TRAP exposure through utilizing targeted approaches, and were consequently restricted to 84 
analyzing a priori known air pollution-associated miRNAs. In the current study, we present for 85 
the first time a global analysis of the circulating miRNome by applying next generation 86 
sequencing technology and real-time exposure measurements in an experimental cross-over 87 
study of human volunteers (n=24) following short-term traffic-related air pollution exposure. 88 
This study demonstrates the potential of circulating miRNAs as novel biomarkers for health risk 89 
assessment in relation to environmental exposure-induced target tissue pathogenesis. 90 
Methods 91 
Selection of the population 92 
Plasma samples were collected during a randomized experimental crossover study in which non-93 
smoking participants, either healthy or suffering from ischemic heart disease (IHD) or chronic 94 
obstructive pulmonary disease (COPD), walked for 2 hours along Oxford Street in London 95 
(where only diesel-powered buses and taxicabs are permitted). In a separate session the same 96 
subjects also walked for 2 hours through traffic-free Hyde Park. In order to balance between 97 
sufficient exposure and what is acceptable for the participants we decided for a 2 hours exposure 98 
window which also has been applied successfully in an earlier study27. Sessions were segregated 99 
by a period of more than 3 weeks.  Participants walked about 6 km during each exposure period, 100 
at a steady pace on predefined paths, resting for 15 minutes every half hour. During each 101 
exposure session, personal ambient air pollution levels of PM were assessed using a real-time 102 
condensation particle counter (Model 3007, TSI). Particles smaller than 2.5 μm in aerodynamic 103 
diameter were collected on an air sampler. BC was measured according to the National Institute 104 
for Occupational Safety and Health guidelines (Method 5040, Sunset Laboratory). Using a 105 
sampling pump, NO2 was collected on C18 Sep-Pak cartridges coated with potassium hydroxide 106 
and triethanolamine and analyzed using ion chromatography27. Our comprehensive monitoring 107 
design aimed to account for each of the major ambient air pollution factors that differed between 108 
sites. To the best of our knowledge there are no major differences with respect to any other 109 
factors not taken into account. In total 119 subjects completed the exposure assessment28. For the 110 
present study, we selected 24 non-smoking participants, based on the maximal change in PM 111 
exposure between Hyde Park and Oxford Street while balancing for gender (Table 1). The study 112 
was approved by the UK National Research Ethics Service (London City Road and Hampstead 113 
Ethics Committee; Research Ethics Number 12/LO/1064, 01/08/2012). All participants gave 114 
written informed consent. The studies were conducted in accordance with the approved 115 
guidelines and regulations.   116 
 # Subjects Age, mean 
(SD) 
BMI, mean 
(SD) 
# Healthy # COPD # IHD 
All subjects 24 65.1 (7.7) 25 (4.8) 8 8 8 
Male 12 65(10) 24.9(3.5) 3 4 5 
Female 12 64.9(5.1) 25.1(6) 5 4 3 
Table 1: Study population data. 117 
Analytical procedures 118 
After each exposure session the participants were transferred to the Royal Brompton Hospital 119 
where blood samples were collected. Plasma samples were recovered from plasma separator 120 
tubes following centrifugation of whole blood at 1,600g for 10 min at 4°C. To avoid 121 
contamination of the plasma cmiRNAs with blood cell-derived miRNAs, the plasma was 122 
subjected to a second centrifugation step at 16,000g before being stored at -80°C29. Plasma 123 
cmiRNAs were isolated using the miRNeasy Serum/Plasma kit (Qiagen) and the quality was 124 
evaluated on a Bioanalyzer using the small RNA Kit (Agilent). Samples were included in the 125 
analysis when showing a minimum of 1 ng RNA yield and a peak at 21 nucleotides. The 126 
sequencing libraries were prepared using the TruSeq Small RNA-Seq Preparation Kit (Illumina), 127 
and sequenced by a HiSeq 2500 (Illumina)30 according to the manufacture’s protocol (GEO 128 
accession: GSE106221).  129 
Statistical data analysis 130 
The quality of the sequencing data was assessed by FastQC and subsequently processed using 131 
the miRge pipeline and miRBase (release 21)31,32. In R, we set a threshold for a cmiRNA to be 132 
detected with a minimum of 100 raw sequencing reads across all samples. The raw data were 133 
quantile normalized and transformed to log2 counts per million (logCPM) using the ‘voom’ 134 
function of the package ‘limma’33. Technical confounders (inter-day variations in library 135 
preparation and isolation batch effects) were adjusted for by applying a linear mixed model 136 
approach using the R package ‘lme4’34. After de-noising the data we used a multivariate normal 137 
model to find associations between the air pollutant exposure and cmiRNA using the R package 138 
‘nlme’35. For each exposure, an independent analysis was performed thereby also adjusting for 139 
sex, age, BMI and disease state (healthy, IHD or COPD). Walks were carried out Monday to 140 
Thursday. No attempt was made to match the day of the week when subjects returned for the 141 
second session as this would have been too restrictive to the subjects. However, the ‘traffic 142 
exposure’ site (Oxford Street) was only open to buses and taxis, with diesel buses representing 143 
the dominant emission source. As bus flows were consistent across all study days, day of the 144 
week was not regarded a significant confounder. Resulting p-values were controlled by the False 145 
Discovery Rate (FDR)  at 5%36.  146 
Potential gene targets were derived from the experimentally validated miRNA-target interactions 147 
database miRTarBase (release 6) by only considering strong miRNA-gene interactions that have 148 
been validated by reporter assay, western blot or qPCR. Overrepresentation analysis of identified 149 
KEGG pathways retrieved from the potential gene targets was performed in ConsensusPathDB 150 
(release 32), using the gene targets for all detected cmiRNAs as a background list. Connections 151 
between pathways and diseases were retrieved from the KEGG DISEASE Database (updated: 152 
September 16, 2016). 153 
To identify potential organs of origin of the detected cmiRNAs, we examined miRNA tissue 154 
enrichment using publicly available small RNA-seq data sets. The data were obtained from the 155 
Human miRNA Expression Database37 as well as from the sequence read archive 156 
(SRA012516)38. The final dataset comprised 101 small RNA sequencing samples across 8 157 
organs known to accumulate inhaled fine PM9-11. We applied a tissue specificity index (TSI), as 158 
described originally for mRNAs by Yanai et al., for each of the significant air pollutant 159 
exposure-associated cmiRNAs. The index is defined as: 160 
TSI =
∑ (1 − 𝑥𝑖)
𝑁
𝑖
𝑁 − 1
 161 
Where N is the number of organs included in the analysis and xi is the expression of a miRNA, 162 
normalized by the value of the highest expressed miRNA39. A TSI < 0.5 indicates that a miRNA 163 
is expressed across all the tissues whereas a higher TSI indicates that a miRNA is enriched in 164 
one or a few tissues. 165 
Results 166 
Exposure range 167 
The subjects analyzed for cmiRNAs were exposed to a mean ambient air NO2 level of 7.9 (CI 168 
5.9-9.8) μg/m3 in Hyde Park and 18.1 (CI 15.1-21.1) μg/m3 in Oxford Street. For PM2.5 the 169 
mean exposure level in Hyde Park was 5.6 (CI 4.5-6.8) μg/m3 and 25.6 (CI 21-30.2) μg/m3  in 170 
Oxford Street. For BC the exposure level was 1.0 (CI 0.8-1.3) μg/m3 in Hyde Park and 11.4 (CI 171 
9.9-12.8) μg/m3 in Oxford Street and for PM10 16.0 (CI 12.5-19.5) μg/m3 in Hyde Park and 37.0 172 
(CI 32.2-41.7) μg/m3 in Oxford Street. For UFP the mean particle count was 5,975 (CI 4815.4-173 
7133.8) thousands/cm3 in Hyde Park and 28,656 (CI 25803-31509) thousands/cm3 in Oxford 174 
Street. The exposure level densities for UFP, PM2.5, BC, PM10 and NO2 are presented in Figure 175 
1. 176 
177 
Figure 1.  TRAP density of the included subjects for cmiRNA analysis. The figure shows the exposure density of 178 
NO2, UFP, PM2.5, BC and PM10 for the included subjects in Hyde Park (HP) and Oxford Street (OX). 179 
Small RNA-sequencing 180 
The sequencing of the 48 samples from 24 subjects yielded a mean of 5.6 million (+/- 2.8 181 
million) high quality, preprocessed reads per sample of which on average 3.8 million (+/- 2.1 182 
million) could be assigned to the miRNA sequences from miRBase (release 21). Principal 183 
component analysis revealed that 2 outliers were present in the data. As a consequence these 2 184 
subjects, as well as 2 further subjects with missing exposure measurements, were excluded from 185 
the analysis. The excluded subjects were not separated by any specific characteristics used in the 186 
analysis (Supplementary Table S1). In total, we identified 595 cmiRNAs across all plasma 187 
samples. The most abundant plasma cmiRNA was miR-486-5p with 19.4 logCPM, followed by 188 
miR-92a (16.6 logCPM), and miR-22-3p (14.4 logCPM). The upper quantile of all identified 189 
cmiRNAs ranged from 4.5 logCPM to 19.4 logCPM, whereas the lower quantile ranged from -190 
3.5 to – 1.4 logCPM. The majority of the cmiRNAs present in the plasma varied between 4.5 and 191 
-3.5 logCPM. 192 
TRAP-associated cmiRNAs 193 
Using the multivariate normal model in combination with the linear mixed model for correction 194 
of technical random effects, we identified cmiRNAs significantly associated with pollutant-195 
specific exposure levels (Figure 2). We observed 6 cmiRNAs to be significantly associated with 196 
the NO2 levels, of which 4 were negatively and 2 positively correlated with exposure. Further, 197 
we identified 7 cmiRNAs, 5 negatively and 2 positively, associated with UFP counts. Analysis of 198 
PM2.5 levels resulted in 23 cmiRNAs, of which 12 were negatively and 11 positively associated 199 
with PM2.5 levels. We observed 26 cmiRNAs to be associated with BC levels of which 14 were 200 
negatively and 12 positively associated with exposure. For PM10 levels we identified 28 201 
cmiRNAs of which 17 were negatively and 11 positively associated with PM10 levels. Together, 202 
the traffic-related air pollutants (NO2, UFP, PM2.5, BC and PM10) were associated to 54 unique 203 
cmiRNAs (Supplementary Table S2). Figure 3 presents the different plasma levels of those 9 204 
cmiRNAs that were declared significant based on the more stringent Bonferroni correction 205 
(ensuring a family-wise error rate <0.05). When comparing the read outs after exposure in Hyde 206 
Park and upon exposure in Oxford Street, we observed decreased miR-133a-3p levels in 95% of 207 
the subjects, in 85 % decreased miR-193b-3p levels, in 80% increased miR-1224-5p levels,  in 208 
85% decreased miR-433-3p levels, in 80% decreased miR-145-5p levels, in 65% decreased miR-209 
27a-5p levels, in 60% decreased miR-580-3p levels, in 55% increased miR-3127-5p levels and in 210 
75% decreased miR-6716-3p levels. This pair-wise comparison clearly demonstrates the 211 
consistency in cmiRNA response to ambient air pollutant exposure among the subjects. We did 212 
not detect any significant results upon stratification by disease state (COPD or IHD vs Healthy) 213 
or gender due to the limited number of samples.  214 
 215 
Figure 2. Pollutant-specific cmiRNAs associated with TRAP exposure. The figure shows the overlap as well as 216 
the specificity of the pollutant-specific cmiRNAs associated with exposure to NO2, UFP, PM2.5, BC and PM10 of 217 
the included subjects in Hyde Park and Oxford Street. 218 
 219 
 220 
Figure 3. Top 9 significant cmiRNAs affected by TRAP exposure. The figure shows the plasma levels of the top 221 
9 significant TRAP-associated cmiRNAs for each subject after walking in Hyde Park (HP) and along Oxford Street 222 
(OX). The red line connects the two measurements per subject. 223 
 224 
Origin of circulating miRNAs 225 
To assess the tissue origin of the detected cmiRNAs, we examined miRNA tissue enrichment 226 
using publicly available small RNA-seq data sets. From the 54 TRAP-affected cmiRNAs, we 227 
identified 7 to be highly expressed (log2CPM > 10) in the lung,  8 in the breast, 3 in the heart, 6 228 
in the kidney, 10 in the liver, 8 in the pancreas, 7 in the spleen and 7 in the brain.  229 
Of the cmiRNAs significantly associated with air pollutant exposure, only 1 (miR-193b-3p)  230 
overlapped with the list of miRNAs associated with hemolysis, indicating that the potential 231 
plasma contamination with miRNAs from red blood cells was minimal40.  232 
By applying a tissue specificity index (TSI) we found that the cmiRNAs that were most abundant 233 
in the plasma, notably miR-25-3p, miR-30d-5p, let-7i-5p, miR-107 (plasma level > 5 log2CPM), 234 
showed a low TSI and were consequently highly abundantly expressed across all target tissues. 235 
By contrast, low abundant cmiRNAs (plasma level < 5 logCPM) showed a high TSI and 236 
appeared to be enriched in only one or just a few tissues. The miRNAs miR-133a-3p and miR-237 
499a-5p, both enriched in the heart with a TSI of 0.60 and 0.64, were present in the plasma at a 238 
mean of 3.7 and -2.1 logCPM, respectively. The brain-enriched miR-433-3p showed a TSI of 239 
0.58 with a plasma level of 0.7 logCPM, while the brain- and pancreas-enriched miR-1224-5p 240 
showed a TSI of 0.68 and was detected in the plasma at 3 logCPM. We identified the kidney-241 
enriched miRNAs miR-3678-3p, miR-6741-3p, miR-6865-5p, miR-4687-5p, hsa-miR-627-3p 242 
and miR-636, all with a TSI > 0.68 and plasma levels < 3.8 logCPM.  Furthermore, we identified 243 
miR-6514-3p to be enriched in the breast, with a TSI of 1 and a plasma level of -2.9 logCPM 244 
(Figure 4).  245 
 246 
247 
Figure 4. Expression of TRAP-associated cmiRNAs across organs known to be targeted by inhaled air 248 
pollutants. The figure shows the mean expression of the high and low abundant cmiRNAs across organs associated 249 
with air pollutant accumulation in logCPM. The data were obtained from the Human miRNA Expression Database37 250 
as well as from the sequence read archive (SRA012516)38. The high abundant cmiRNAs appeared to be 251 
housekeeping miRNAs (miR-25-3p, miR-30d-5p, let-7i-5p, and miR-107), while the low abundant cmiRNAs 252 
seemed to show organ specificity/enrichment. 253 
Disease associations, Target genes and Pathway analysis 254 
To investigate the potential involvement of the 54 identified cmiRNAs in air pollutant-related 255 
diseases, we explored known disease-miRNA interactions from published studies found in 256 
PubMed and miRWalk (version 2.0). We identified 8 interactions with breast cancer, 3 257 
interactions with cardiovascular diseases, 5 interactions with inflammation, 8 interactions with 258 
respiratory disease (incl. lung cancer and Asthma), 6 interactions with neurodegenerative 259 
diseases (incl. Alzheimer’s Disease and Parkinson) and 4 interaction with kidney diseases (Table 260 
2). 261 
Disease 
# 
Associations/interactions miRNAs 
References 
Breast cancer 8 
miR-107↑; 
miR-125a-
5p↓; miR-
145-5p↓; 
miR-150-
5p↓; miR-
193b-3p↓; 
miR-342-
3p↓; miR-
34a-5p↓; 
miR-98-5p↑ 
41-48 
Cardiovascular 
Disease 3 
miR-133a↓; 
miR-145-
5p↓; miR-
499a-5p↓ 
49-51 
Inflammation 5 
let-7i-5p↑; 
miR-107↑; 
miR-223-
3p↓; miR-
25-3p↑; 
miR-miR-
98-5p↑ 
52-55 
Kidney Diseases 4 
miR-25-
3p↑; miR-
148a-3p↑; 
miR-150-
5p↓; miR-
223-3p↓ 
56 
Neurodegenerative 
diseases (incl. 
Alzheimer’s Disease 
and Parkinson) 6 
miR-107↑; 
miR-1224-
5p↑; miR-
145-5p↓; 
miR-34a-
5p↓; miR-
433-3p↓; 
miR-885-
5p↓ 
54,57-61 
Respiratory 
Diseases (incl. lung 8 
let-7i-5p↑; 
miR-107↑; 
43,52,62,63 
cancer and asthma) miR-125a-
5p↓; miR-
145-5p↓; 
miR-148a-
3p↑; miR-
223-3p↓; 
miR-574-
5p↑ miR-
98-5p↑ 
Table 2. Overlap between miRNAs found to be altered in diseased tissue and cmiRNAs to 262 
be associated with air pollutant exposure. (↑) indicates cmiRNAs to be positively associated 263 
and (↓) negatively associated with the exposure levels. The miRNAs marked in bold show the 264 
same directionality in subjects exposed air pollution exposure and in patients suffering from a 265 
particular disease. 266 
 267 
To further describe the functional relevance of air pollutant exposure-associated cmiRNAs, we 268 
explored their potential interactions with gene targets from the experimentally validated miRNA-269 
target interactions database miRTarBase (release 6, only strong interactions). We identified a set 270 
of 491 target genes for the air pollutant exposure-associated 54 cmiRNAs. We explored the 271 
relationship between these cmiRNAs and their respective target genes by performing an 272 
overrepresentation analysis of KEGG pathways using ConsensusPathDB (release 32). This 273 
analysis identified 31 KEGG pathways (Supplementary Table S3). Notably, the list of 274 
overrepresented pathways includes significantly modified cancer-related pathways such as 275 
microRNAs in cancer, specifically breast cancer, non-small cell lung cancer and small cell lung 276 
cancer as well as signaling pathways such as the PI3K-Akt signaling pathway and the p53 277 
signaling pathway.  278 
Discussion 279 
In this study, we evaluated the global circulating miRNome in plasma from human subjects 280 
exposed to ambient TRAP for only 2 hours by using NGS. We identified 54 cmiRNAs that 281 
appear to be involved in the molecular response to NO2, UFP, PM2.5, BC and PM10 exposure. 282 
Next, we gathered information on tissue-specific miRNAs from those organs known to be 283 
targeted by ambient air pollutants. We found that the most abundant cmiRNAs present in plasma 284 
are equally expressed in all organs known to be targeted by TRAP. By contrast, the cmiRNAs 285 
present at low plasma levels appeared to be specifically enriched in certain target organs (TSI 286 
>0.5) (Figure 4). The inverse association between high TSI and lower plasma level (correlation 287 
coefficient = -0.68) thus suggests that lower expressed (logCPM < 5) cmiRNAs might 288 
particularly represent tissue-specific biomarkers. Therefore, we hypothesize that the low 289 
abundant cmiRNAs are promising markers for the evaluation of tissue and organ conditions 290 
reflected by non-invasive ‘liquid biopsies’. In contrast to studies in which miRNAs may leak into 291 
the circulation upon high exposures to toxic compounds, such as a consequence of 292 
acetaminophen-induced cytotoxicity in the liver30, ambient TRAP levels are unlikely to induce 293 
cell death within 2 hours of time, implying that the induced alterations of cmiRNAs are more 294 
likely to reflect the active release of specific miRNAs into the circulation13. 295 
Ambient TRAP exposure has been implicated in the development of cardiovascular disease1, 296 
respiratory disease3,  kidney disease8, several types of cancer4,5, as well as in neurodegenerative 297 
diseases6,7. This is now also suggested on the molecular level by our results on tissue- and 298 
disease-specific cmiRNAs following short-term exposure to ambient TRAP. We demonstrated 299 
that the heart-enriched miR-133a-3p was significantly decreased in the plasma of 95 percent of 300 
the participants upon increased exposure. Downregulation or deletion of this miRNA has been 301 
associated with cardiac hypertrophy, severe fibrosis and heart failure. A study on the partial 302 
knockdown of miR-133 in mice has shown to induce hypertrophy during cardiac diseases64. 303 
Furthermore, the complete knockout of both miR-133 genes resulted in late embryonic or 304 
neonatal lethality due to ventricular septal defects in the majority of the mice, whereas mice that 305 
survived to adulthood developed extensive myocardial fibrosis and finally died from heart 306 
failure65.  307 
The smooth muscle cell-enriched miR-145-5p was significantly decreased in 80% of the 308 
participants upon exposure to TRAP. This miRNA, which has been reported to be downregulated 309 
in the carotid artery upon mechanical injury, is involved in regulation of smooth muscle 310 
contractility and the stress response to vessel injury, and thus is involved in cardiovascular 311 
diseases50. 312 
Furthermore, we observed TRAP-dependent downregulation of the heart-enriched miR-499a-5p, 313 
a miRNA that is known to be downregulated under pathological heart conditions and has been 314 
suggested as a pharmacological target in the treatment of apoptosis-related cardiac disease, 315 
including myocardial infarction51.  316 
Overall, the two heart-enriched miRNAs miR-133a-3p and miR-499a-5p as well as the smooth 317 
muscle cell-enriched miR-145-5p play a crucial role in the development of cardiovascular 318 
diseases which is known to be associated with exposure to TRAP, and therefore add potential 319 
value to a miRNA-based biomarker catalogue for cardiovascular disease prevention and 320 
biomarker-based environmental health risk assessment.  321 
We observed, in 85% of the subjects decreased plasma levels of miR-193b-3p in relation to 322 
higher TRAP exposure levels. The downregulation of this miRNA in breast tissue is known to 323 
enhance tumor progression and invasion in human breast cancer45. Also, the plasma level of 324 
miR-145-5p was decreased in 80 % of participants, a miRNA that inhibits growth and migration 325 
of breast cancer66. Furthermore, miR-145-5p has also been identified to inhibit the proliferation 326 
of non-small cell lung cancer cells by targeting the oncogene c-Myc, and increasing the 327 
expression of miR-145 has been suggested as a novel approach for the treatment of lung 328 
cancer43. 329 
Potentially, the TRAP-induced inhibitions of miR-193b-3p and miR-145-5p play a role in the 330 
complex progress of cancer development upon ambient air pollution exposure. Furthermore, in 331 
association with air pollutant exposure levels we identified another 4 decreased cmiRNAs (miR-332 
125a-5, miR-150-5p, miR-342-3p and miR-34a-5p) and 2 increased cmiRNAs (miR-107 and 333 
miR-98-5p) for which a role in breast and/or lung cancer development has been described41-48. 334 
The upregulation of miRNAs let-7i-5p and miR-98-5p has been shown to decrease IL-13 levels 335 
which resulted in the resolution of airway inflammation52. In this study we identified both 336 
miRNAs to be increased in plasma upon higher TRAP levels, thus potentially indicating a 337 
protective mechanism against increasing inflammation in the airways and circulation 27. We also 338 
identified the asthma-associated miRNAs miR-223-3p with decreased and miR-574-5p with 339 
increased plasma levels upon higher TRAP exposure. In lung tissue of mice challenged with 340 
ovalbumin mimicking acute, intermediate and chronic asthma, the downregulation of miR-223-341 
3p to short term, and the upregulation of miR-574 to long term exposure to allergens has been 342 
reported62. 343 
Recently, TRAP exposure has also been linked to an increased risk of neurodegenerative 344 
diseases such as Alzheimer’s and Parkinson’s disease7. We observed significantly decreased 345 
plasma levels of the brain-enriched miR-433-3p (85 % of all subjects) after exposure. This 346 
miRNA has also been found to be significantly decreased in the serum and cerebrospinal fluid of 347 
Parkinson’s and Alzheimer’s diseases patients when compared to healthy individuals61. The 348 
downregulation of cmiRNAs is unlikely to reflect cell damage as a consequence of toxic 349 
exposure, but rather suggests a biological response by a signalling molecule to a change in 350 
ambient air pollutant exposure intensity.  351 
Plasma levels of another brain-enriched miRNA, miR-1224-5p, appeared increased in 80 % of 352 
the study participants. This miRNA has been experimentally shown to silence LRRK2, which is 353 
known to be down-regulated during pathogenesis of Parkinson’s disease67,68.  354 
In patients diagnosed with Alzheimer’s Disease, decreased serum levels of circulating miR-885 355 
have been described59. Also in our study we have observed decreased plasma levels of this 356 
miRNA in association with TRAP exposure. Furthermore, miR-107 and miR-34a-5p, both highly 357 
abundant in brain tissue, were found to be decreased in serum even in patients at the earliest 358 
stages of Alzheimer’s Disease54,60. While we observed increased miR-107 plasma levels with 359 
increased exposure intensity, miR-34a-5p levels were indeed decreased upon exposure.  360 
Furthermore, we identified 4 TRAP-associated miRNAs, namely miR-25-3p, miR-148a-3p, 361 
miR-150-5 and miR-223-3p, which are known to be implicated in the pathogenesis and 362 
progression of kidney diseases56. The miRNA which we identified most abundantly expressed in 363 
kidney, miR-148a-3p, was increased in plasma following higher TRAP levels. A closely related 364 
family member of this miRNA, miR-148b-3p, was found upregulated in peripheral blood 365 
mononuclear cells in patients suffering from igA nephropathy69. More recently, serum levels of 366 
miR-148b-3p have been described as a potential non-invasive biomarker for diagnosing igA 367 
nephropathy70. Interestingly, another study described low levels of miR-223-3p in circulating 368 
endothelial cells as a noninvasive method for evaluating the severity of igA nephropathy71. In 369 
our analysis we found lower levels of miR-223-3p with increased TRAP levels. Our tissue 370 
specificity analysis revealed that miR-148a-3p and miR-223 are not enriched in kidney and were 371 
found abundantly expressed in other tissues (TSI < 0.37). However, we identified another 6 372 
kidney-enriched miRNAs (TSI > 0.68) that have not been sufficiently described in literature and 373 
might play a role in environmentally induced kidney diseases.  374 
We evaluated the potential biological function of the cmiRNA signature by determining target 375 
genes, pathways and disease associations. The analysis showed that relevant disease pathways 376 
such as microRNAs in cancer, breast cancer, non-small cell lung cancer and small cell lung 377 
cancer as well as signaling pathways such as the PI3K-Akt signaling pathway and the p53 378 
signaling pathway are potentially perturbed by exposure to ambient air pollution. 379 
An earlier study reported 2 vesicle-associated cmiRNAs to be increased upon short-term 380 
exposure to metal-rich PM (miR-128 and miR-302) in healthy workers13. In our analysis we 381 
observed decreased miR-128 levels but no change in miR-302 levels after short-term exposure. 382 
Another study on extracellular vesicle-bound cmiRNAs reported levels of 5 miRNAs to be 383 
changed after 6 months and 1 year in relation to ambient PM2.5 levels. Further 1 significantly 384 
decreased miRNA (miR-30d-5p) was reported after 1 day of exposure25. This cmiRNA has also 385 
been identified in our analysis with significant decreased plasma levels already after 2 hours of 386 
exposure to TRAP.  387 
In this study we applied NGS to capture the complete plasma circulating miRNome and therefore 388 
were able to detect cmiRNAs that have not been investigated in relation to TRAP exposure 389 
previously. Despite the relatively small sample size, the experimental cross-over design of the 390 
study combined with the personal exposure monitoring enabled us to find significant associations 391 
of cmiRNAs and TRAP in the selected population.  392 
The limited sample size, however, did not allow a meaningful analysis after stratification by 393 
disease state (COPD or IHD vs healthy) or gender. A hierarchical clustering analysis confirmed 394 
that cmiRNA expression is not confounded by disease status (data not shown). As a consequence 395 
of the study design in which COPD and IHD subjects were matched to healthy controls of the 396 
same age our analysis is limited to subjects of a mean age of 65.1 years (SD 7.7). Therefore the 397 
results need to be validated in other age groups to evaluate to which degree the results are 398 
transferable to other age groups. Due to the limited organ coverage of the human miRNA tissue 399 
atlas our analysis of miRNA tissue origin has been based on publically available sequencing data 400 
from various laboratories and therefore only suggests a potential origin of the detected cmiRNA. 401 
In summary, by applying stringent statistical analyses we have shown that the circulating 402 
miRNome is altered already after 2 hours of exposure to ambient air pollution in a dose- and 403 
pollutant species-dependent manner. The cmiRNA signature seems to be capable to identify 404 
molecular mechanisms that upon perturbation by TRAP exposure are possibly involved in the 405 
complex pathogenesis of multiple diseases. Strikingly, the miRNA profile identified already after 406 
2 hours of TRAP exposure, presents specific associations with all major disease risks reported in 407 
relation to exposure to ambient air pollution. Next to the known disease risks that are affected by 408 
TRAP exposure our data also suggests aberrant abundance of circulating miRNAs that 409 
potentially have originated from the liver, pancreas and spleen. Since in addition, animal studies 410 
have demonstrated that in particular liver and spleen also present target organs for TRAP we 411 
suggest that future epidemiological studies should consider these organs to unravel their potential 412 
role in TRAP-associated pathology. Overall, our findings will not only contribute to the 413 
understanding of the complex coherence of environmental exposure and miRNAs but also 414 
provide insights into the pathomolecular process of TRAP-induced diseases, and thereby 415 
substantiate to biomarker-based health risk assessment.Consequently, we propose that a cmiRNA 416 
signature comprised of organ-enriched miRNAs presents a highly specific candidate for 417 
biomarker-based health risk assessment allowing the early detection and prevention of TRAP-418 
induced health outcomes.  419 
 420 
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